Lilly Launches Initiative to Expand Diabetes, Obesity Drug Access
MT Newswires Live
Sep 28
Eli Lilly (LLY) said Monday it launched a global initiative to expand access to its diabetes and obesity medicines in low- and middle-income countries.
Under the Lilly Change the Course Commitment, the company said it plans to treat as many patients in resource-limited countries as in high-income countries with its diabetes and obesity medicines by 2040.
Lilly said it plans to expand clinical development, regulatory approvals and access in these countries and work with health organizations to strengthen local healthcare systems.
The company said it will focus on countries in Africa, Latin America and Asia and report progress through its annual sustainability report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.